BONESUPPORT Q3: Initial take – sales in line, beat on EBIT - Redeye

Redeye sees another quarter in which BONESUPPORT delivers well on sales (beating our US CERAMENT G sales figures), and we expect the market to appreciate the robust EBIT. In short, Q3 was a solid quarter, but the report should not send any shockwaves today. We expect a 2-3% positive share price reaction.

Länk till analysen i sin helhet: https://www.redeye.se/research/1045676/bonesupport-q3-initial-take-sales-in-line-beat-on-ebit?utm_source=finwire&utm_medium=RSS